{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:02:28Z","timestamp":1791475348146,"version":"4.3.4"},"reference-count":373,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.purol.2022.07.148","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T21:55:37Z","timestamp":1668549337000},"page":"1275-1372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-2152","authenticated-orcid":false,"given":"G.","family":"Ploussard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Brureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gauth\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Rozet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ruffion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-B.","family":"Beauval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.annonc.2020.02.009","article-title":"European cancer mortality predictions for the year 2020 with a focus on prostate cancer","volume":"31","author":"Carioli","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.purol.2022.07.148_bib0010","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.purol.2015.04.011","article-title":"[Prostate cancer incidence and mortality trends in France from 1980 to 2011]","volume":"25","author":"Grosclaude","year":"2015","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ijc.32287","article-title":"Endocrine disrupting-chemicals and biochemical recurrence of prostate cancer after prostatectomy: a cohort study in Guadeloupe (French West Indies)","volume":"146","author":"Brureau","year":"2020","journal-title":"Int J Cancer"},{"issue":"21","key":"10.1016\/j.purol.2022.07.148_bib0020","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2009.27.2153","article-title":"Chlordecone exposure and risk of prostate cancer","volume":"28","author":"Multigner","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.purol.2022.07.148_bib0025","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1186\/s12889-015-2260-x","article-title":"Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada","volume":"15","author":"Blanc-Lapierre","year":"2015","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0030","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/BF03346748","article-title":"Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis","volume":"36","author":"Esposito","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"10.1016\/j.purol.2022.07.148_bib0035","first-page":"1603","article-title":"The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium","volume":"26","author":"Davies","year":"2015","journal-title":"Cancer Causes Control"},{"issue":"12","key":"10.1016\/j.purol.2022.07.148_bib0040","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1158\/1055-9965.EPI-14-0795","article-title":"Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study","volume":"23","author":"Vidal","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"10.1016\/j.purol.2022.07.148_bib0045","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.urolonc.2020.04.008","article-title":"Testosterone replacement therapy (TRT) and prostate cancer: an updated systematic review with a focus on previous or active localized prostate cancer","volume":"38","author":"Lenfant","year":"2020","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0050","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.2008.864","article-title":"Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"301","author":"Lippman","year":"2009","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.purol.2022.07.148_bib0055","first-page":"1208","article-title":"Using medicare claims to examine long-term prostate cancer risk of finasteride in the prostate cancer prevention trial","volume":"110","author":"Unger","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"10.1016\/j.purol.2022.07.148_bib0060","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0070","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.eururo.2014.04.027","article-title":"Metformin use and prostate cancer risk","volume":"66","author":"Preston","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1870","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/pcan.2013.10","article-title":"Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study","volume":"16","author":"Freedland","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1875","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2014.30","article-title":"Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease","volume":"110","author":"Leongamornlert","year":"2014","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0085","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00439-012-1229-4","article-title":"HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)","volume":"132","author":"Xu","year":"2013","journal-title":"Hum Genet"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0090","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2018.11.015","article-title":"Homeobox B13 G84E mutation and prostate cancer risk","volume":"75","author":"Nyberg","year":"2019","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.purol.2022.07.148_bib0095","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/pros.23795","article-title":"The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis","volume":"79","author":"Oh","year":"2019","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0100","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1158\/0008-5472.CAN-19-1840","article-title":"Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness","volume":"80","author":"Patel","year":"2020","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.purol.2022.07.148_bib0105","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/ng.3094","article-title":"A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer","volume":"46","author":"Al Olama","year":"2014","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.purol.2022.07.148_bib0110","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41588-018-0142-8","article-title":"Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci","volume":"50","author":"Schumacher","year":"2018","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0115","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.purol.2021.12.007","article-title":"[DNA repair gene alterations testing in prostate cancer: a practical update by the prostate cancer committee of the French Association of Urology]","volume":"32","author":"Ploussard","year":"2022","journal-title":"Prog Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0120","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0125","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0130","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0135","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT Study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/jnci\/djab147","article-title":"Breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers using polygenic risk scores","volume":"114","author":"Barnes","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.purol.2022.07.148_bib0145","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.annonc.2020.06.025","article-title":"Imaging-based prostate cancer screening among BRCA mutation carriers\u00a0\u2013\u00a0results from the first round of screening","volume":"31","author":"Segal","year":"2020","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0150","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate Cancer, Version 2.2019, NCCN Clinical practice guidelines in oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eururo.2018.08.026","article-title":"Mutational profile of aggressive, localised prostate cancer from African Caribbean men versus European ancestry men","volume":"75","author":"Tonon","year":"2019","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.purol.2022.07.148_bib0160","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.purol.2022.07.148_bib0165","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0170","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0175","first-page":"CD004720","article-title":"Screening for prostate cancer","author":"Ilic","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.purol.2022.07.148_bib0180","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jama.2014.2085","article-title":"Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence","volume":"311","author":"Hayes","year":"2014","journal-title":"JAMA"},{"issue":"9959","key":"10.1016\/j.purol.2022.07.148_bib0185","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up","volume":"384","author":"Schroder","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0190","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the european randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.eururo.2012.11.041","article-title":"Health-related quality of life in the Finnish trial of screening for prostate cancer","volume":"65","author":"Booth","year":"2014","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.purol.2022.07.148_bib0200","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3109\/0284186X.2013.802837","article-title":"Effects of prostate cancer screening on health-related quality of life: results of the Finnish arm of the European randomized screening trial (ERSPC)","volume":"52","author":"Vasarainen","year":"2013","journal-title":"Acta Oncol"},{"issue":"7","key":"10.1016\/j.purol.2022.07.148_bib0205","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa1201637","article-title":"Quality-of-life effects of prostate-specific antigen screening","volume":"367","author":"Heijnsdijk","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0210","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2019.04.033","article-title":"Structured population-based prostate-specific antigen screening for prostate cancer: the European Association of Urology position in 2019","volume":"76","author":"Gandaglia","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0215","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pros.22925","article-title":"Prostate cancer risk prediction based on complete prostate cancer family history","volume":"75","author":"Albright","year":"2015","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.purol.2022.07.148_bib0220","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/pros.21314","article-title":"Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer","volume":"71","author":"Chornokur","year":"2011","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0225","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eururo.2021.12.011","article-title":"Defining the impact of family history on detection of high-grade prostate cancer in a large multi-institutional cohort","volume":"82","author":"Clements","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0230","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.euo.2021.09.001","article-title":"Prostate cancer screening with magnetic resonance imaging: results from the second round of the Goteborg Prostate Cancer Screening 2 Trial","volume":"5","author":"Wallstrom","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0235","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2006.06.9351","article-title":"Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years","volume":"25","author":"Lilja","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.purol.2022.07.148_bib0240","doi-asserted-by":"crossref","first-page":"f2023","DOI":"10.1136\/bmj.f2023","article-title":"Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long-term risk of metastasis: case-control study","volume":"346","author":"Vickers","year":"2013","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.purol.2022.07.148_bib0245","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2016.66.7527","article-title":"Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer","volume":"34","author":"Preston","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0250","doi-asserted-by":"crossref","first-page":"e1919284","DOI":"10.1001\/jamanetworkopen.2019.19284","volume":"3","author":"Kovac","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.purol.2022.07.148_bib0255","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jnci\/djaa001","article-title":"Lifetime benefits and harms of prostate-specific antigen-based risk-stratified screening for prostate cancer","volume":"112","author":"Heijnsdijk","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0260","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.euo.2021.06.006","article-title":"A European model for an organised risk-stratified early detection programme for prostate cancer","volume":"4","author":"Van Poppel","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0265","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2008.03.104","article-title":"The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam","volume":"54","author":"Gosselaar","year":"2008","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.purol.2022.07.148_bib0270","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level\u00a0<\u00a0or\u00a0=\u00a04.0\u00a0ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.purol.2022.07.148_bib0275","doi-asserted-by":"crossref","first-page":"829","DOI":"10.6004\/jnccn.2018.7278","article-title":"Digital rectal examination remains a key prognostic tool for prostate cancer: a national cancer database review","volume":"17","author":"Borkenhagen","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0280","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/pros.20286","article-title":"Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden","volume":"65","author":"Bruun","year":"2005","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0285","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41391-017-0024-7","article-title":"Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer","volume":"21","author":"Nordstrom","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0290","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/s41391-021-00373-w","article-title":"Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models","volume":"24","author":"Stavrinides","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"17.","key":"10.1016\/j.purol.2022.07.148_bib0295","article-title":"Biomarker in active surveillance for prostate cancer: a systematic review","volume":"13","author":"Manceau","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0300","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.euf.2017.02.017","article-title":"Prognostic biomarkers used for localised prostate cancer management: a systematic review","volume":"4","author":"Lamy","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0305","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1148\/radiol.13122393","article-title":"Real-time contrast-enhanced transrectal US-guided prostate biopsy: diagnostic accuracy in men with previously negative biopsy results and positive MR imaging findings","volume":"269","author":"Cornelis","year":"2013","journal-title":"Radiology"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0310","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.juro.2015.12.086","article-title":"Limitations of elastography based prostate biopsy","volume":"195","author":"Schiffmann","year":"2016","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0315","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.euo.2018.10.001","article-title":"Comparison of the diagnostic accuracy of micro-ultrasound and magnetic resonance imaging\/ultrasound fusion targeted biopsies for the diagnosis of clinically significant prostate cancer","volume":"2","author":"Lughezzani","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0320","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.juro.2015.12.093","article-title":"Assessing cancer risk on novel 29\u00a0MHz micro-ultrasound images of the prostate: creation of the micro-ultrasound protocol for prostate risk identification","volume":"196","author":"Ghai","year":"2016","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0325","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1097\/JU.0000000000001639","article-title":"Micro-ultrasound-guided vs. multiparametric magnetic resonance imaging-targeted biopsy in the detection of prostate cancer: a systematic review and meta-analysis","volume":"205","author":"Sountoulides","year":"2021","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0330","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00345-021-03890-4","article-title":"Use of high-resolution micro-ultrasound to predict extraprostatic extension of prostate cancer prior to surgery: a prospective single-institutional study","volume":"40","author":"Fasulo","year":"2022","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0335","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System Version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0340","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JU.0000000000000617","article-title":"Update of the standard operating procedure on the use of multiparametric magnetic resonance imaging for the diagnosis, staging and management of prostate cancer","volume":"203","author":"Bjurlin","year":"2020","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0345","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.eururo.2019.05.029","article-title":"High diagnostic performance of short magnetic resonance imaging protocols for prostate cancer detection in biopsy-naive men: the next step in magnetic resonance imaging accessibility","volume":"76","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0350","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2214\/AJR.20.24268","article-title":"PI-RADS Committee Position on MRI without contrast medium in biopsy-naive men with suspected prostate cancer: narrative review","volume":"216","author":"Schoots","year":"2021","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0355","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2019.06.023","article-title":"Prostate magnetic resonance imaging, with or Without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis","volume":"77","author":"Drost","year":"2020","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0360","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1148\/radiol.2482070157","article-title":"Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis","volume":"248","author":"Tamada","year":"2008","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0365","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1148\/radiol.10100667","article-title":"Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?","volume":"258","author":"Turkbey","year":"2011","journal-title":"Radiology"},{"issue":"19","key":"10.1016\/j.purol.2022.07.148_bib0370","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0375","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamaoncol.2020.7589","article-title":"Comparison of multiparametric magnetic resonance imaging-targeted biopsy with systematic transrectal ultrasonography biopsy for biopsy-naive men at risk for prostate cancer: a phase 3 randomized clinical trial","volume":"7","author":"Klotz","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0380","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","article-title":"Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study","volume":"20","author":"Rouviere","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0385","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.purol.2022.07.148_bib0390","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstrom","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.purol.2022.07.148_bib0395","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0400","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.euo.2020.08.014","article-title":"Combined use of prostate-specific antigen density and magnetic resonance imaging for prostate biopsy decision planning: a retrospective multi-institutional study using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD)","volume":"4","author":"Falagario","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.purol.2022.07.148_bib0405","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejrad.2019.02.028","article-title":"Comparison of PET\/MRI with multiparametric MRI in diagnosis of primary prostate cancer: a meta-analysis","volume":"113","author":"Li","year":"2019","journal-title":"Eur J Radiol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0410","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous (68)Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0415","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2214\/AJR.18.19585","article-title":"Improving diagnosis of primary prostate cancer with combined (68)Ga-prostate-specific membrane antigen-HBED-CC simultaneous PET and multiparametric MRI and clinical parameters","volume":"211","author":"Jena","year":"2018","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0420","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.purol.2020.10.003","article-title":"[Short recommendations from the CIAFU: interest of the urine bacterial culture performed before endo-rectal prostate biopsy]","volume":"31","author":"Bruyere","year":"2021","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0425","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.acvd.2018.10.004","volume":"112","author":"Godier","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0430","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1464-410x.2000.00576.x","article-title":"Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study","volume":"85","author":"Aron","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2022.07.148_bib0435","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2016.12.011","article-title":"Prostate biopsy-related infection: a systematic review of risk factors, prevention strategies, and management approaches","volume":"104","author":"Roberts","year":"2017","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0440","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.juro.2014.07.086","article-title":"Prosbiotate: a multicenter, prospective analysis of infectious complications after prostate biopsy","volume":"193","author":"Bruyere","year":"2015","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0445","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/JU.0000000000001399","article-title":"Nonantibiotic strategies for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis","volume":"205","author":"Pradere","year":"2021","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0450","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/pcan.2017.13","article-title":"Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach","volume":"20","author":"Bass","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0455","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.prnil.2021.05.003","article-title":"Topical antiseptic at time of transrectal ultrasound prostate biopsy is associated with fewer severe clinical infections and improves antibiotic stewardship","volume":"9","author":"Ramedani","year":"2021","journal-title":"Prostate Int"},{"key":"10.1016\/j.purol.2022.07.148_bib0460","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.urology.2020.06.005","article-title":"A systematic review and meta-analysis of methods used to reduce infectious complications following transrectal prostate biopsy","volume":"144","author":"Jazayeri","year":"2020","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0465","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.euo.2020.12.012","article-title":"Magnetic resonance imaging\/ultrasound fusion-guided transperineal versus magnetic resonance imaging\/ultrasound fusion-guided transrectal prostate biopsy\u00a0\u2013\u00a0a systematic review","volume":"4","author":"Rai","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0470","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.euo.2021.06.001","article-title":"Managing discordant findings between multiparametric magnetic resonance imaging and transrectal magnetic resonance imaging-directed prostate biopsy\u00a0\u2013\u00a0the key role of magnetic resonance imaging-directed transperineal biopsy","volume":"5","author":"Bajeot","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0475","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/jcm9010225","article-title":"Assessment of the minimal targeted biopsy core number per MRI lesion for improving prostate cancer grading prediction","volume":"9","author":"Ploussard","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0480","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2019.04.008","article-title":"Role of core number and location in targeted magnetic resonance imaging-ultrasound fusion prostate biopsy","volume":"76","author":"Lu","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0485","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/JU.0000000000000527","article-title":"Minimum magnetic resonance imaging-ultrasound fusion targeted biopsy cores needed for prostate cancer detection: multivariable retrospective, lesion based analyses of patients treated with radical prostatectomy","volume":"203","author":"Leyh-Bannurah","year":"2020","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0490","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2018.11.040","article-title":"The FUTURE Trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies","volume":"75","author":"Wegelin","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0495","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41391-021-00449-7","article-title":"Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis","volume":"25","author":"Bass","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"16","key":"10.1016\/j.purol.2022.07.148_bib0500","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.purol.2020.09.012","article-title":"What to expect from a non-suspicious prostate MRI? A review","volume":"30","author":"Fiard","year":"2020","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0505","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/JU.0000000000001414","article-title":"Negative prebiopsy magnetic resonance imaging and risk of significant prostate cancer: baseline and long-term follow-up results","volume":"205","author":"Buisset","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0510","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/JU.0000000000000757","article-title":"Predictive factors of missed clinically significant prostate cancers in men with negative magnetic resonance imaging: a systematic review and meta-analysis","volume":"204","author":"Pagniez","year":"2020","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0515","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.purol.2020.09.025","article-title":"Should we perform systematic biopsies in case of suspicious MRI for prostate cancer in 2020? A review of literature","volume":"31","author":"Vesval","year":"2021","journal-title":"Prog Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0520","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/bju.15568","article-title":"The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia","volume":"129","author":"Morote","year":"2022","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0525","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.eururo.2016.08.004","article-title":"Complications after systematic, random, and image-guided prostate biopsy","volume":"71","author":"Borghesi","year":"2017","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.purol.2022.07.148_bib0530","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma","volume":"44","author":"van Leenders","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0535","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5858\/arpa.2020-0015-RA","article-title":"The 2019 Genitourinary Pathology Society (GUPS) white paper on contemporary grading of prostate cancer","volume":"145","author":"Epstein","year":"2021","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0540","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0545","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A Contemporary prostate cancer grading system: a validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.07.148_bib0550","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bju.15556","article-title":"The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade","volume":"128 Suppl. 3","author":"Hennes","year":"2021","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0555","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2019.07.051","article-title":"Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups","volume":"77","author":"van Leenders","year":"2020","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.purol.2022.07.148_bib0560","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/PAS.0b013e3182217b79","article-title":"Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings","volume":"35","author":"Karram","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0565","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.euo.2018.03.013","article-title":"Features and prognostic significance of intraductal carcinoma of the prostate","volume":"1","author":"Montironi","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"S1","key":"10.1016\/j.purol.2022.07.148_bib0570","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1038\/modpathol.2017.138","article-title":"High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate","volume":"31","author":"Zhou","year":"2018","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0575","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/modpathol.2010.178","article-title":"International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 1: specimen handling","volume":"24","author":"Samaratunga","year":"2011","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0580","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/modpathol.2010.160","article-title":"International Society of Urological Pathology (ISUP) consensus conference on handling and staging of radical prostatectomy specimens. Working group 4: seminal vesicles and lymph nodes","volume":"24","author":"Berney","year":"2011","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0585","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/PAP.0b013e318220f5b1","article-title":"Treatment effects in the prostate including those associated with traditional and emerging therapies","volume":"18","author":"Evans","year":"2011","journal-title":"Adv Anat Pathol"},{"issue":"18","key":"10.1016\/j.purol.2022.07.148_bib0590","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/jnci\/djm117","article-title":"Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial","volume":"99","author":"Lucia","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0595","doi-asserted-by":"crossref","first-page":"360","DOI":"10.5858\/2007-131-360-DOPCAT","article-title":"Diagnosis of prostatic carcinoma after therapy","volume":"131","author":"Bostwick","year":"2007","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0600","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2018.01.043","article-title":"Clinical and genomic characterization of low-prostate-specific antigen, high-grade prostate cancer","volume":"74","author":"Mahal","year":"2018","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0605","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.eururo.2019.09.027","article-title":"Predicting prostate cancer death with different pretreatment risk stratification tools: a head-to-head comparison in a nationwide cohort study","volume":"77","author":"Zelic","year":"2020","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0610","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","article-title":"Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0615","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","article-title":"Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis","volume":"70","author":"de Rooij","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0620","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2214\/ajr.166.4.8610561","article-title":"Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology","volume":"166","author":"Jager","year":"1996","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0625","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1148\/radiol.2372041724","article-title":"Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers","volume":"237","author":"Futterer","year":"2005","journal-title":"Radiology"},{"issue":"10","key":"10.1016\/j.purol.2022.07.148_bib0630","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s00330-012-2475-5","article-title":"Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI","volume":"22","author":"Bloch","year":"2012","journal-title":"Eur Radiol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0635","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1148\/radiol.2321031086","article-title":"Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension","volume":"232","author":"Wang","year":"2004","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0640","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2012.11324.x","article-title":"An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011","volume":"111","author":"Eifler","year":"2013","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0645","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2011.10.044","article-title":"Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores","volume":"61","author":"Briganti","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0650","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2018.10.012","article-title":"A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies","volume":"75","author":"Gandaglia","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0655","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"Hovels","year":"2008","journal-title":"Clin Radiol"},{"key":"10.1016\/j.purol.2022.07.148_bib0660","doi-asserted-by":"crossref","first-page":"476786","DOI":"10.1155\/2013\/476786","article-title":"What is the clinical significance of FDG unexpected uptake in the prostate in patients undergoing PET\/CT for other malignancies?","volume":"2013","author":"Bhosale","year":"2013","journal-title":"Int J Mol Imaging"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0665","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.eururo.2008.04.030","article-title":"et al., 11C-choline positron emission tomography\/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms","volume":"54","author":"Schiavina","year":"2008","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0670","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00345-013-1189-x","article-title":"(1)(8)F-fluorocholine PET\/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer","volume":"32","author":"Kjolhede","year":"2014","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0675","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.09.039","article-title":"Utility of choline positron emission tomography\/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis","volume":"63","author":"Evangelista","year":"2013","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0680","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00259-020-04995-5","article-title":"Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET\/CT and its relationship with modified D\u2019Amico risk classification","volume":"48","author":"Simsek","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0685","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2967\/jnumed.120.245605","article-title":"(68)Ga-PSMA PET\/CT for primary lymph node and distant metastasis NM staging of high-risk prostate cancer","volume":"62","author":"Klingenberg","year":"2021","journal-title":"J Nucl Med"},{"issue":"10231","key":"10.1016\/j.purol.2022.07.148_bib0690","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0695","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00259-020-05025-0","article-title":"PET\/MRI in prostate cancer: a systematic review and meta-analysis","volume":"48","author":"Evangelista","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.purol.2022.07.148_bib0700","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.euros.2021.09.006","volume":"33","author":"Ling","year":"2021","journal-title":"Eur Urol Open Sci"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0705","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2014.05.011","article-title":"More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer","volume":"67","author":"Abdollah","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0710","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/iju.12184","article-title":"Sentinel lymph node dissection in more than 1200 prostate cancer cases: rate and prediction of lymph node involvement depending on preoperative tumor characteristics","volume":"21","author":"Winter","year":"2014","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0715","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.eururo.2012.06.057","article-title":"Mapping of pelvic lymph node metastases in prostate cancer","volume":"63","author":"Joniau","year":"2013","journal-title":"Eur Urol"},{"issue":"6 Pt 1","key":"10.1016\/j.purol.2022.07.148_bib0720","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1097\/01.ju.0000123981.03084.06","article-title":"Baseline staging of newly diagnosed prostate cancer: a summary of the literature","volume":"171","author":"Abuzallouf","year":"2004","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0725","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00259-013-2532-6","article-title":"Whole-body SPECT\/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients","volume":"41","author":"Palmedo","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.purol.2022.07.148_bib0730","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s00330-010-1879-3","article-title":"Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and measure bone metastases in prostate cancer (PCa)","volume":"20","author":"Lecouvet","year":"2010","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0735","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00256-009-0789-4","article-title":"Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma","volume":"39","author":"Gutzeit","year":"2010","journal-title":"Skeletal Radiol"},{"issue":"11","key":"10.1016\/j.purol.2022.07.148_bib0740","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","article-title":"Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis","volume":"43","author":"Shen","year":"2014","journal-title":"Skeletal Radiol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0745","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/bju.12599","article-title":"Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)\/computed tomography (CT) and [(18) F]NaF PET\/CT","volume":"114","author":"Poulsen","year":"2014","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0750","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.euo.2020.06.012","volume":"4","author":"Anttinen","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0755","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnumed.114.150391","article-title":"18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry","volume":"56","author":"Hillner","year":"2015","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0760","first-page":"448","article-title":"Fluorocholine (18F) and sodium fluoride (18F) PET\/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading","volume":"55","author":"Langsteger","year":"2011","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.purol.2022.07.148_bib0765","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.2010.31.2330","article-title":"Impact of comorbidity on survival among men with localized prostate cancer","volume":"29","author":"Albertsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.purol.2022.07.148_bib0770","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1056\/NEJMoa1807801","article-title":"Radical prostatectomy or watchful waiting in prostate cancer\u00a0\u2013\u00a029-year follow-up","volume":"379","author":"Bill-Axelson","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0775","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.eururo.2020.02.009","article-title":"Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT)","volume":"77","author":"Wilt","year":"2020","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.purol.2022.07.148_bib0780","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.purol.2022.07.148_bib0785","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0790","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2019.10.030","article-title":"Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received","volume":"77","author":"Neal","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0795","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/bju.15048","article-title":"A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings","volume":"126","author":"Luzzago","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2022.07.148_bib0800","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.urology.2019.10.039","article-title":"Impact of MRI and targeted biopsies on eligibility and disease reclassification in MRI-positive candidates for active surveillance on systematic biopsies","volume":"137","author":"Ploussard","year":"2020","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0805","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","article-title":"Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis","volume":"80","author":"Rajwa","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0810","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2214\/AJR.20.23985","article-title":"Update on multiparametric prostate MRI during active surveillance: current and future trends and role of the PRECISE recommendations","volume":"216","author":"Giganti","year":"2021","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0815","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.eururo.2016.06.011","article-title":"Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations\u00a0\u2013\u00a0a report of a European School of Oncology Task Force","volume":"71","author":"Moore","year":"2017","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0820","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","article-title":"Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up","volume":"77","author":"Klotz","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0825","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.eururo.2019.02.035","article-title":"The value of an extensive transrectal repeat biopsy with anterior sampling in men on active surveillance for low-risk prostate cancer: a comparison from the randomised study of active monitoring in Sweden (SAMS)","volume":"76","author":"Bratt","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0830","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","article-title":"EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an International Collaborative Study (DETECTIVE Study)","volume":"76","author":"Lam","year":"2019","journal-title":"Eur Urol"},{"issue":"16","key":"10.1016\/j.purol.2022.07.148_bib0835","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1200\/JCO.2010.32.8112","article-title":"Active surveillance program for prostate cancer: an update of the Johns Hopkins experience","volume":"29","author":"Tosoian","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0840","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0845","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11845-013-1024-9","article-title":"A single centre experience of active surveillance as management strategy for low-risk prostate cancer in Ireland","volume":"183","author":"Forde","year":"2014","journal-title":"Ir J Med Sci"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0850","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2013.02.020","article-title":"Medium-term outcomes of active surveillance for localised prostate cancer","volume":"64","author":"Selvadurai","year":"2013","journal-title":"Eur Urol"},{"issue":"5\u20136","key":"10.1016\/j.purol.2022.07.148_bib0855","doi-asserted-by":"crossref","first-page":"171","DOI":"10.5489\/cuaj.2806","article-title":"Active surveillance for the management of localized prostate cancer: guideline recommendations","volume":"9","author":"Morash","year":"2015","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0860","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.juro.2015.01.102","article-title":"Gleason upgrading with time in a large prostate cancer active surveillance cohort","volume":"194","author":"Jain","year":"2015","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0865","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","article-title":"Long-term follow-up of a large active surveillance cohort of patients with prostate cancer","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib0870","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2012.11.005","article-title":"Active surveillance for low-risk prostate cancer worldwide: the PRIAS study","volume":"63","author":"Bul","year":"2013","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.purol.2022.07.148_bib0875","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.04.015","article-title":"Active surveillance for low-risk prostate cancer: need for intervention and survival at 10 years","volume":"33","author":"Preston","year":"2015","journal-title":"Urol Oncol"},{"issue":"1 Suppl.","key":"10.1016\/j.purol.2022.07.148_bib0880","first-page":"S19","article-title":"A multi-institutional evaluation of active surveillance for low risk prostate cancer","volume":"189","author":"Eggener","year":"2013","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0885","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.eururo.2012.08.066","article-title":"Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial","volume":"63","author":"Godtman","year":"2013","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0890","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2014.06.010","article-title":"Five-year nationwide follow-up study of active surveillance for prostate cancer","volume":"67","author":"Loeb","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0895","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2015.06.011","article-title":"Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer","volume":"68","author":"Filippou","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0900","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/cncr.24882","article-title":"Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?","volume":"116","author":"van den Bergh","year":"2010","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.purol.2022.07.148_bib0905","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S1470-2045(13)70366-8","article-title":"Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study","volume":"14","author":"Ornish","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0910","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cct.2014.05.002","article-title":"A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance])","volume":"38","author":"Parsons","year":"2014","journal-title":"Contemp Clin Trials"},{"issue":"9821","key":"10.1016\/j.purol.2022.07.148_bib0915","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(11)61619-X","article-title":"Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial","volume":"379","author":"Fleshner","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.purol.2022.07.148_bib0920","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"370","author":"Bill-Axelson","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib0925","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.critrevonc.2009.09.005","article-title":"Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults","volume":"73","author":"Droz","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0930","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2013.02.025","article-title":"Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial","volume":"64","author":"Bill-Axelson","year":"2013","journal-title":"Eur Urol"},{"issue":"10049","key":"10.1016\/j.purol.2022.07.148_bib0935","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(16)30592-X","article-title":"Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study","volume":"388","author":"Yaxley","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0940","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00345-021-03878-0","article-title":"Annual nationwide analysis of costs and post-operative outcomes after radical prostatectomy according to the surgical approach (open, laparoscopic, and robotic)","volume":"40","author":"Ploussard","year":"2022","journal-title":"World J Urol"},{"issue":"8","key":"10.1016\/j.purol.2022.07.148_bib0945","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S1470-2045(18)30357-7","article-title":"Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study","volume":"19","author":"Coughlin","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib0950","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/bju.14062","article-title":"Laparoscopic and robot-assisted vs. open radical prostatectomy for the treatment of localized prostate cancer: a Cochrane systematic review","volume":"121","author":"Ilic","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2022.07.148_bib0955","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2020.06.009","article-title":"One-day prehabilitation program before robotic radical prostatectomy in daily practice: routine feasibility and benefits for patients and hospitals","volume":"21","author":"Ploussard","year":"2020","journal-title":"Eur Urol Open Sci"},{"issue":"18","key":"10.1016\/j.purol.2022.07.148_bib0960","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1002\/cncr.33061","article-title":"A combination of enhanced recovery after surgery and prehabilitation pathways improves perioperative outcomes and costs for robotic radical prostatectomy","volume":"126","author":"Ploussard","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0965","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.eururo.2015.11.004","article-title":"Preoperative pelvic floor muscle exercise and postprostatectomy incontinence: a systematic review and meta-analysis","volume":"69","author":"Chang","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib0970","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/JU.0000000000002205","article-title":"An algorithm to personalize nerve sparing in men with unilateral high-risk prostate cancer","volume":"207","author":"Martini","year":"2022","journal-title":"J Urol"},{"issue":"6 Pt 2","key":"10.1016\/j.purol.2022.07.148_bib0975","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1464-410X.2011.10565.x","article-title":"Anatomical grades of nerve sparing: a risk-stratified approach to neural-hammock sparing during robot-assisted radical prostatectomy (RARP)","volume":"108","author":"Tewari","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.purol.2022.07.148_bib0980","first-page":"CD013641","article-title":"Retzius-sparing versus standard robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer","volume":"8","author":"Rosenberg","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib0985","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.eururo.2009.11.034","article-title":"Comprehensive standardized report of complications of retropubic and laparoscopic radical prostatectomy","volume":"57","author":"Rabbani","year":"2010","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib0990","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.eururo.2009.01.036","article-title":"Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies","volume":"55","author":"Ficarra","year":"2009","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.purol.2022.07.148_bib0995","first-page":"1654","article-title":"Functional outcomes after treatment for prostate cancer","volume":"368","author":"Resnick","year":"2013","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.purol.2022.07.148_bib1000","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/jnci\/dji313","article-title":"et al., 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity","volume":"97","author":"Alibhai","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1005","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.eururo.2015.02.029","article-title":"Urinary incontinence and erectile dysfunction after robotic versus open radical prostatectomy: a prospective, controlled, nonrandomised trial","volume":"68","author":"Haglind","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.eururo.2007.04.020","article-title":"Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy","volume":"52","author":"Heidenreich","year":"2007","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.juro.2007.03.018","article-title":"Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%","volume":"178","author":"Touijer","year":"2007","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1020","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.eururo.2006.08.015","article-title":"Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer","volume":"50","author":"Briganti","year":"2006","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","article-title":"The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review","volume":"72","author":"Fossati","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1030","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.euo.2021.03.006","article-title":"Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial","volume":"4","author":"Touijer","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1035","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eururo.2020.11.040","article-title":"Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial","volume":"79","author":"Lestingi","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2022.07.148_bib1040","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.urology.2019.09.040","article-title":"Ten-year treatment outcomes of radical prostatectomy vs. external beam radiation therapy vs. brachytherapy for 1503 patients with intermediate-risk prostate cancer","volume":"136","author":"Goy","year":"2020","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.brachy.2019.10.005","article-title":"Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy","volume":"19","author":"Tom","year":"2020","journal-title":"Brachytherapy"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.5114\/jcb.2017.70763","article-title":"Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy?: Results of two prospective randomized trials","volume":"9","author":"Merrick","year":"2017","journal-title":"J Contemp Brachytherapy"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1055","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijrobp.2017.09.050","article-title":"Prospective phase 2 trial of permanent seed implantation prostate brachytherapy for intermediate-risk localized prostate cancer: efficacy, toxicity, and quality of life outcomes","volume":"100","author":"Frank","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1060","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/jama.2019.20675","article-title":"Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"323","author":"Hoffman","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.brachy.2017.10.001","article-title":"Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19\u00a0Gy high-dose-rate brachytherapy","volume":"17","author":"Mendez","year":"2018","journal-title":"Brachytherapy"},{"issue":"12","key":"10.1016\/j.purol.2022.07.148_bib1070","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1200\/JCO.2017.75.9134","article-title":"Brachytherapy-based radiotherapy and radical prostatectomy are associated with similar survival in high-risk localized prostate cancer","volume":"36","author":"Ennis","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.purol.2022.07.148_bib1075","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9-10 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.purol.2022.07.148_bib1080","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ctrv.2018.10.004","article-title":"Brachytherapy versus external beam radiotherapy boost for prostate cancer: systematic review with meta-analysis of randomized trials","volume":"70","author":"Kee","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1090","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1095","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijrobp.2017.02.027","article-title":"ASCENDE-RT: an analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1100","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.brachy.2018.12.007","article-title":"A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer","volume":"18","author":"King","year":"2019","journal-title":"Brachytherapy"},{"issue":"15","key":"10.1016\/j.purol.2022.07.148_bib1105","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC Trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1110","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol"},{"issue":"31","key":"10.1016\/j.purol.2022.07.148_bib1115","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.purol.2022.07.148_bib1120","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","year":"2016","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.purol.2022.07.148_bib1125","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.purol.2022.07.148_bib1130","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.purol.2022.07.148_bib1135","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","article-title":"Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer","volume":"34","author":"Lee","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1140","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.canrad.2017.11.004","article-title":"Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: the French genito-urinary group (GETUG) recommendations","volume":"22","author":"Langrand-Escure","year":"2018","journal-title":"Cancer Radiother"},{"issue":"10196","key":"10.1016\/j.purol.2022.07.148_bib1145","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1150","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.purol.2022.07.148_bib1155","doi-asserted-by":"crossref","first-page":"103661","DOI":"10.1016\/j.critrevonc.2022.103661","article-title":"Highly hypofractionated schedules for localized prostate cancer: recommendations of the GETUG radiation oncology group","volume":"173","author":"Lapierre","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"10.1016\/j.purol.2022.07.148_bib1160","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1165","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2013.04.039","article-title":"Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: oncologic outcomes and morbidity in 1002 patients","volume":"65","author":"Crouzet","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1170","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1464-410X.2012.11715.x","article-title":"Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer","volume":"112","author":"Ganzer","year":"2013","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1175","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.juro.2013.02.010","article-title":"Evolution and outcomes of 3\u00a0MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years","volume":"190","author":"Thuroff","year":"2013","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.purol.2022.07.148_bib1180","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1464-410X.2011.10251.x","article-title":"Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer","volume":"108","author":"Boutier","year":"2011","journal-title":"BJU Int"},{"issue":"49","key":"10.1016\/j.purol.2022.07.148_bib1185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19490","article-title":"Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation","volume":"19","author":"Ramsay","year":"2015","journal-title":"Health Technol Assess"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1190","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.euf.2019.11.014","article-title":"High-intensity focused ultrasound for the treatment of prostate cancer: a national cohort study focusing on the development of stricture and fistulae","volume":"7","author":"Dosanjh","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1195","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2013.04.004","article-title":"Cryotherapy and its applications in the management of urologic malignancies: a review of its use in prostate and renal cancers","volume":"32","author":"Mohammed","year":"2014","journal-title":"Urol Oncol"},{"issue":"13","key":"10.1016\/j.purol.2022.07.148_bib1200","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/pros.23030","article-title":"A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate","volume":"75","author":"Elshafei","year":"2015","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1205","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.juro.2009.05.041","article-title":"Primary cryoablation nadir prostate specific antigen and biochemical failure","volume":"182","author":"Levy","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.purol.2022.07.148_bib1210","article-title":"Detailing sexual outcomes after focal therapy for localised prostate cancer: a systematic review and meta-analysis","author":"Fiard","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"8\u20139","key":"10.1016\/j.purol.2022.07.148_bib1215","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.purol.2019.05.004","article-title":"[Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review]","volume":"29","author":"Kleinclauss","year":"2019","journal-title":"Prog Urol"},{"issue":"10","key":"10.1016\/j.purol.2022.07.148_bib1220","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00345-019-02636-7","article-title":"Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project","volume":"37","author":"van Luijtelaar","year":"2019","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1225","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2012.05.011","article-title":"Focal therapy of prostate cancer: energies and procedures","volume":"31","author":"Bozzini","year":"2013","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1230","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/bju.14951","article-title":"Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment","volume":"125","author":"Blazevski","year":"2020","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.purol.2022.07.148_bib1235","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1172\/JCI70354","article-title":"Tracking the clonal origin of lethal prostate cancer","volume":"123","author":"Haffner","year":"2013","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1240","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eururo.2014.10.026","article-title":"Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review","volume":"68","author":"Valerio","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1245","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2018.01.001","article-title":"Focal therapy in primary localised prostate cancer: the European Association of Urology Position in 2018","volume":"74","author":"van der Poel","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1250","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/pcan.2017.8","article-title":"Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project","volume":"20","author":"Tay","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1255","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.eururo.2014.09.018","article-title":"Focal therapy: patients, interventions, and outcomes\u00a0\u2013\u00a0a report from a consensus meeting","volume":"67","author":"Donaldson","year":"2015","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1260","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.eururo.2014.01.001","article-title":"Focal therapy in prostate cancer: international multidisciplinary consensus on trial design","volume":"65","author":"van den Bos","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1265","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2015.06.018","article-title":"Focal high-intensity focused ultrasound targeted hemiablation for unilateral prostate cancer: a prospective evaluation of oncologic and functional outcomes","volume":"69","author":"Feijoo","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1270","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2021.08.005","article-title":"An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?","volume":"81","author":"Hopstaken","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1275","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2016.09.039","article-title":"Focal high intensity focused ultrasound of unilateral localized prostate cancer: a prospective multicentric hemiablation study of 111 patients","volume":"71","author":"Rischmann","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1280","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bju.15004","article-title":"Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry","volume":"125","author":"Lovegrove","year":"2020","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1285","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","article-title":"A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer","volume":"74","author":"Guillaumier","year":"2018","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.purol.2022.07.148_bib1290","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/j.1464-410X.2011.10578.x","article-title":"Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry","volume":"109","author":"Ward","year":"2012","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1295","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(16)30661-1","article-title":"Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial","volume":"18","author":"Azzouzi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1300","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.eururo.2020.05.003","article-title":"Techniques and outcomes of salvage robot-assisted radical prostatectomy (sRARP)","volume":"78","author":"De Groote","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1305","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.clon.2021.10.012","article-title":"Comparative effectiveness analyses of salvage prostatectomy and salvage radiotherapy outcomes following focal or whole-gland ablative therapy (high-intensity focused ultrasound, cryotherapy or electroporation) for localised prostate cancer","volume":"34","author":"Nathan","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"15","key":"10.1016\/j.purol.2022.07.148_bib1310","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1315","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.purol.2022.07.148_bib1320","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/cncr.28609","article-title":"The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease","volume":"120","author":"Keane","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/pcan.2016.51","article-title":"Active surveillance for intermediate-risk prostate cancer","volume":"20","author":"Dall\u2019Era","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1330","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.juro.2016.06.102","article-title":"Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook Experience","volume":"196","author":"Musunuru","year":"2016","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1530","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0090-4295(94)90180-5","article-title":"Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases","volume":"43","author":"Partin","year":"1994","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1335","doi-asserted-by":"crossref","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.purol.2022.07.148_bib1340","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1001\/jama.2015.8577","article-title":"Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer","volume":"314","author":"D\u2019Amico","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1345","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.purol.2022.07.148_bib1350","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/JCO.21.00855","article-title":"Short androgen suppression and radiation dose escalation in prostate cancer: 12-year results of EORTC Trial 22991 in patients with localized intermediate-risk disease","volume":"39","author":"Bolla","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1355","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2022.04.003","article-title":"High-dose radiotherapy or androgen deprivation therapy (HEAT) as treatment intensification for localized prostate cancer: an individual patient-data network meta-analysis from the MARCAP Consortium","volume":"82","author":"Kishan","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1360","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1365","doi-asserted-by":"crossref","first-page":"e216871","DOI":"10.1001\/jamaoncol.2021.6871","article-title":"Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer: a patient-level data analysis of 3 cohorts","volume":"8","author":"Kishan","year":"2022","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1370","doi-asserted-by":"crossref","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs. dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.purol.2022.07.148_bib1375","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejca.2020.10.023","article-title":"Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: a randomised phase III trial","volume":"143","author":"Nabid","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1380","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2021.04.013","article-title":"Optimizing treatment in intermediate-risk prostate cancer: secondary analysis of a randomized phase 3 trial","volume":"111","author":"Nabid","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1385","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.ijrobp.2007.11.056","article-title":"Selecting patients for exclusive permanent implant prostate brachytherapy: the experience of the Paris Institut Curie\/Cochin Hospital\/Necker Hospital group on 809 patients","volume":"71","author":"Cosset","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1390","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2014.01.020","article-title":"Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study","volume":"67","author":"Joniau","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1395","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/j.ijrobp.2011.04.037","article-title":"Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease","volume":"81","author":"Stenmark","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.purol.2022.07.148_bib1400","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1405","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.ijrobp.2009.10.007","article-title":"Timing of salvage hormonal therapy in prostate cancer patients with unfavorable prognosis treated with radiotherapy: a secondary analysis of Radiation Therapy Oncology Group 85-31","volume":"78","author":"Souhami","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"19","key":"10.1016\/j.purol.2022.07.148_bib1410","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1200\/JCO.2014.57.7510","article-title":"Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer","volume":"33","author":"Mason","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1415","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.eururo.2016.03.021","volume":"70","author":"Fossa","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1420","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(18)30757-5","volume":"20","author":"Denham","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1425","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial","volume":"74","author":"Nabid","year":"2018","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.purol.2022.07.148_bib1430","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrurol.2016.100","article-title":"Prostate cancer: combining endocrine treatment and radiotherapy: a bright future","volume":"13","author":"Roach","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1435","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.20.02438","article-title":"Prostate radiotherapy with adjuvant androgen deprivation therapy (ADT) improves metastasis-free survival compared to neoadjuvant ADT: an individual patient meta-analysis","volume":"39","author":"Spratt","year":"2021","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.purol.2022.07.148_bib1440","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.25900","article-title":"Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer","volume":"117","author":"Boorjian","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.purol.2022.07.148_bib1445","doi-asserted-by":"crossref","first-page":"g1502","DOI":"10.1136\/bmj.g1502","article-title":"Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes","volume":"348","author":"Sooriakumaran","year":"2014","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1450","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.clgc.2014.01.010","article-title":"Radical prostatectomy or radiotherapy in high-risk prostate cancer: a systematic review and metaanalysis","volume":"12","author":"Petrelli","year":"2014","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1455","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.purol.2022.07.148_bib1460","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1470-2045(15)00011-X","article-title":"Androgen deprivation therapy plus doc\u00e9taxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial","volume":"16","author":"Fizazi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10024","key":"10.1016\/j.purol.2022.07.148_bib1465","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of doc\u00e9taxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.purol.2022.07.148_bib1470","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG Oncology RTOG 0521 Trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.purol.2022.07.148_bib1475","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1480","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2022.03.031","article-title":"Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavourable prostate cancer: a systematic review and meta-analysis","volume":"82","author":"Rajwa","year":"2022","journal-title":"Eur Urol"},{"issue":"10323","key":"10.1016\/j.purol.2022.07.148_bib1485","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1490","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eururo.2012.03.053","article-title":"Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial","volume":"62","author":"Mottet","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1495","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.euo.2019.02.001","article-title":"A Systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer","volume":"2","author":"Ventimiglia","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1500","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.eururo.2017.08.011","article-title":"Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis","volume":"73","author":"Seisen","year":"2018","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1505","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \u201cDoc\u00e9taxel Era\u201d: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1510","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE Trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1515","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.euo.2018.09.015","article-title":"Association between radical prostatectomy and survival in men with clinically node-positive prostate cancer","volume":"2","author":"Sarkar","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1520","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.purol.2022.07.148_bib1525","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1464-410X.2009.08518.x","article-title":"High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure","volume":"104","author":"Blana","year":"2009","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1535","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1540","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.euo.2021.01.003","article-title":"Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy","volume":"4","author":"Panebianco","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1545","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.purol.2014.12.002","article-title":"[Imagery of treated prostate cancer]","volume":"25","author":"Renard-Penna","year":"2015","journal-title":"Prog Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1550","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ijrobp.2010.07.1975","article-title":"Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?","volume":"81","author":"Zapatero","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1555","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/RLU.0b013e318266cc38","article-title":"Role of 18F-choline PET\/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution","volume":"38","author":"Marzola","year":"2013","journal-title":"Clin Nucl Med"},{"issue":"Suppl. 3","key":"10.1016\/j.purol.2022.07.148_bib1560","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.2967\/jnumed.115.169755","article-title":"11C- or 18F-choline PET\/CT for imaging evaluation of biochemical recurrence of prostate cancer","volume":"57","author":"Mapelli","year":"2016","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.purol.2022.07.148_bib1565","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00345-018-2547-5","article-title":"Impact of sodium (18)F-fluoride PET\/CT, (18)F-fluorocholine PET\/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study","volume":"37","author":"Gauthe","year":"2019","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1570","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/RLU.0b013e3182867f3c","article-title":"Choline PET or PET\/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis","volume":"38","author":"Evangelista","year":"2013","journal-title":"Clin Nucl Med"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1575","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.purol.2022.07.148_bib1580","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3390\/cancers13071594","article-title":"Restaging the biochemical recurrence of prostate cancer with [(68)Ga]Ga-PSMA-11 PET\/CT: diagnostic performance and impact on patient disease management","volume":"13","author":"Fourquet","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.purol.2022.07.148_bib1585","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2967\/jnumed.119.226381","article-title":"A prospective study on (18)F-DCFPyL PSMA PET\/CT imaging in biochemical recurrence of prostate cancer","volume":"60","author":"Rousseau","year":"2019","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1590","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ijrobp.2020.01.050","article-title":"Effect of (18)F-Fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON Trial","volume":"107","author":"Scarsbrook","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10288","key":"10.1016\/j.purol.2022.07.148_bib1595","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"(18)F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.purol.2022.07.148_bib1600","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"(18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9858","key":"10.1016\/j.purol.2022.07.148_bib1605","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1610","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","article-title":"Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial","volume":"181","author":"Thompson","year":"2009","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1615","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.purol.2022.07.148_bib1620","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10260","key":"10.1016\/j.purol.2022.07.148_bib1625","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.purol.2022.07.148_bib1630","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10260","key":"10.1016\/j.purol.2022.07.148_bib1635","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.purol.2022.07.148_bib1640","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1200\/JCO.2016.68.3425","article-title":"Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer","volume":"34","author":"Stish","year":"2016","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.purol.2022.07.148_bib1645","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1200\/JCO.20.03714","article-title":"Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death","volume":"39","author":"Tilki","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1650","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1655","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","article-title":"A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1660","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1665","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.eururo.2008.09.043","volume":"55","author":"Briganti","year":"2009","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1670","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2009.12.034","article-title":"Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer","volume":"57","author":"Engel","year":"2010","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1675","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.euo.2020.08.005","article-title":"Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review","volume":"3","author":"Marra","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"35","key":"10.1016\/j.purol.2022.07.148_bib1680","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2013.54.7893","article-title":"Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer","volume":"32","author":"Abdollah","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1685","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.euo.2021.01.001","article-title":"Management of persistently elevated prostate-specific antigen after radical prostatectomy: a systematic review of the literature","volume":"4","author":"Ploussard","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1690","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.urology.2008.07.067","article-title":"Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy?","volume":"74","author":"Godoy","year":"2009","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1695","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00345-013-1214-0","article-title":"Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study","volume":"32","author":"Ploussard","year":"2014","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1700","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.eururo.2022.01.012","article-title":"Restaging of patients with persistently elevated prostate-specific antigen after radical prostatectomy using [(68)Ga]-PSMA-11 positron emission tomography\/computed tomography: impact on disease management","volume":"81","author":"Gauthe","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1705","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.eururo.2013.08.013","article-title":"Early salvage radiotherapy following radical prostatectomy","volume":"65","author":"Pfister","year":"2014","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1710","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.eururo.2019.11.023","article-title":"Salvage radiotherapy versus hormone therapy for prostate-specific antigen failure after radical prostatectomy: a randomised, multicentre, open-label, phase 3 trial (JCOG0401)(dagger)","volume":"77","author":"Yokomizo","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1715","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","article-title":"Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09\/10 randomized phase 3 trial","volume":"80","author":"Ghadjar","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1720","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijrobp.2019.09.047","article-title":"Toxicity and biochemical outcomes of dose-intensified postoperative radiation therapy for prostate cancer: results of a randomized phase III trial","volume":"106","author":"Qi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10338","key":"10.1016\/j.purol.2022.07.148_bib1725","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1730","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of (68)Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","author":"Roach","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.purol.2022.07.148_bib1735","doi-asserted-by":"crossref","first-page":"742093","DOI":"10.3389\/fonc.2021.742093","article-title":"PET\/CT-based salvage radiotherapy for recurrent prostate cancer after radical prostatectomy: impact on treatment management and future directions","volume":"11","author":"le Guevelou","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1740","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.purol.2022.07.148_bib1745","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1750","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.purol.2022.07.148_bib1755","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","article-title":"Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy","volume":"34","author":"Tendulkar","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.purol.2022.07.148_bib1760","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","article-title":"Prostate cancer-specific survival following salvage radiotherapy vs. observation in men with biochemical recurrence after radical prostatectomy","volume":"299","author":"Trock","year":"2008","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1765","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2012.01.022","article-title":"Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature","volume":"61","author":"Chade","year":"2012","journal-title":"Eur Urol"},{"issue":"6\u20137","key":"10.1016\/j.purol.2022.07.148_bib1770","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.canrad.2017.07.026","article-title":"Management of local relapse after prostate cancer radiotherapy: surgery or radiotherapy?","volume":"21","author":"Hennequin","year":"2017","journal-title":"Cancer Radiother"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1775","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ijrobp.2021.10.138","article-title":"Salvage low-dose-rate prostate brachytherapy: clinical outcomes of a phase 2 trial for local recurrence after external beam radiation therapy (NRG Oncology\/RTOG 0526)","volume":"112","author":"Crook","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1780","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.purol.2022.07.148_bib1785","doi-asserted-by":"crossref","first-page":"e026666","DOI":"10.1136\/bmjopen-2018-026666","article-title":"GETUG-AFU 31: a phase I\/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol","volume":"9","author":"Pasquier","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1790","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.radonc.2012.09.014","article-title":"Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes","volume":"105","author":"Crouzet","year":"2012","journal-title":"Radiother Oncol"},{"issue":"9\u201310","key":"10.1016\/j.purol.2022.07.148_bib1795","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5489\/cuaj.3113","article-title":"Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer","volume":"9","author":"Siddiqui","year":"2015","journal-title":"Can Urol Assoc J"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1800","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2012.02.051","article-title":"Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy","volume":"61","author":"Mouraviev","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2022.07.148_bib1805","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2010.12.012","article-title":"Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer","volume":"60","author":"Williams","year":"2011","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2022.07.148_bib1810","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1815","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.eururo.2015.11.023","article-title":"Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review","volume":"69","author":"van den Bergh","year":"2016","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.purol.2022.07.148_bib1820","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1825","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00345-016-1932-1","article-title":"Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project","volume":"35","author":"Scheltema","year":"2017","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1830","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.juro.2015.04.103","article-title":"Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature","volume":"194","author":"Ploussard","year":"2015","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1835","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2018.10.041","article-title":"Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review","volume":"76","author":"Ploussard","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.purol.2022.07.148_bib1840","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.eururo.2020.06.043","article-title":"Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought","volume":"78","author":"Bravi","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1845","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate Cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1850","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00259-018-4159-0","article-title":"Salvage extended field or involved field nodal irradiation in (18)F-fluorocholine PET\/CT oligorecurrent nodal failures from prostate cancer","volume":"46","author":"Lepinoy","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.purol.2022.07.148_bib1855","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.eururo.2014.02.011","article-title":"Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years","volume":"67","author":"Suardi","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2022.07.148_bib1860","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2018.09.009","article-title":"Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis","volume":"75","author":"Fossati","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2022.07.148_bib1865","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00066-014-0763-5","article-title":"Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only","volume":"191","author":"Rischke","year":"2015","journal-title":"Strahlenther Onkol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670872200344X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S116670872200344X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:37:23Z","timestamp":1761115043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S116670872200344X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":373,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S116670872200344X"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2022.07.148","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2022.07.148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}